Department of Obstetrics and Gynecology, Far Eastern Memorial Hospital, Banqiao, New Taipei 220409, Taiwan.
Department of Obstetrics and Gynecology, National Taiwan University College of Medicine and the Hospital, Taipei 100225, Taiwan.
Int J Environ Res Public Health. 2020 Aug 16;17(16):5941. doi: 10.3390/ijerph17165941.
to elucidate the predictors of progression-free survival (PFS) and overall survival (OS) in high-risk endometrial cancer patients. the medical records of all consecutivewomen with high-risk endometrial cancer were reviewed. among 92 high-risk endometrial cancer patients, 30 women experienced recurrence, and 21 women died. The 5-year PFS and OS probabilities were 65.3% and 75.9%, respectively. Multivariable Cox regression revealed that body mass index (hazard ratio (HR) = 1.11), paraaortic lymph node metastasis (HR = 11.11), lymphovascular space invasion (HR = 5.61), and sandwich chemoradiotherapy (HR = 0.15) were independently predictors of PFS. Body mass index (HR = 1.31), paraaortic lymph node metastasis (HR = 32.74), non-endometrioid cell type (HR = 11.31), and sandwich chemoradiotherapy (HR = 0.07) were independently predictors of OS. Among 51 women who underwent sandwich ( = 35) or concurrent ( = 16) chemoradiotherapy, the use of sandwich chemoradiotherapy were associated with better PFS (adjusted HR = 0.26, 95% CI = 0.08-0.87, = 0.03) and OS (adjusted HR = 0.11, 95% CI = 0.02-0.71, = 0.02) compared with concurrent chemoradiotherapy. compared with concurrent chemoradiotherapy, sandwich chemoradiotherapy was associated with better PFS and OS in high-risk endometrial cancer patients. In addition, high body mass index, paraaortic lymph node metastasis, and non-endometrioid cell type were also predictors of poor OS in high-risk endometrial cancer patients.
为了阐明高危子宫内膜癌患者无进展生存期（PFS）和总生存期（OS）的预测因素。回顾了所有连续患有高危子宫内膜癌的女性的病历。在 92 例高危子宫内膜癌患者中，30 例患者出现复发，21 例患者死亡。5 年 PFS 和 OS 概率分别为 65.3%和 75.9%。多变量 Cox 回归显示，体重指数（危险比（HR）= 1.11）、腹主动脉旁淋巴结转移（HR = 11.11）、淋巴血管空间侵犯（HR = 5.61）和夹心放化疗（HR = 0.15）是 PFS 的独立预测因素。体重指数（HR = 1.31）、腹主动脉旁淋巴结转移（HR = 32.74）、非子宫内膜样细胞类型（HR = 11.31）和夹心放化疗（HR = 0.07）是 OS 的独立预测因素。在接受夹心（n = 35）或同期（n = 16）放化疗的 51 名女性中，夹心放化疗与更好的 PFS（调整后的 HR = 0.26，95%CI = 0.08-0.87，P = 0.03）和 OS（调整后的 HR = 0.11，95%CI = 0.02-0.71，P = 0.02）相关，与同期放化疗相比。与同期放化疗相比，夹心放化疗与高危子宫内膜癌患者更好的 PFS 和 OS 相关。此外，高体重指数、腹主动脉旁淋巴结转移和非子宫内膜样细胞类型也是高危子宫内膜癌患者 OS 不良的预测因素。
